You are here

Article Text

Article menu
Download PDFPDF
Editorial
The new MedTech Europe directive: implications for educational activities in pathology and laboratory medicine
  1. Tahir S Pillay
  1. Department of Chemical Pathology, Faculty of Health Sciences, University of Pretoria, Pretoria, South Africa
  1. Correspondence to Professor Tahir S Pillay, Department of Chemical Pathology, Faculty of Health Sciences, University of Pretoria, Pretoria 0007, South Africa; jclinpatheic{at}gmail.com

https://doi.org/10.1136/jclinpath-2017-204372

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    As in all branches and specialties in medicine, educational activities and conferences are an essential part of training and continuous professional development and this is also mandated by statutory licensing bodies. Traditionally, industry has supported many educational activities in medicine. These have included support for congresses, workshops and other meetings. Many annual congresses and conferences rely heavily on support from both the pharmaceutical and medical technology industries. In the case of pathology, the predominant support is from the medical technology companies, as would be expected. MedTech Europe is the trade association that represents the medical technology industries including the manufacturers of diagnostic instruments and medical devices. MedTech Europe was formed in October 2012 from an alliance of European Diagnostic Manufacturer's Association, representing the European in vitro diagnostic industry and Eucomed representing the medical devices industry.

    MedTech Europe recently introduced a code of practice1 for companies, which is being implemented in 2018 with a transition period in 2017. After the 2017 transition period, member companies can no longer provide financial or in kind support to individual pathologists to cover costs of attendance at congresses with the exception of third-party-organised procedure training meetings or if a pathologist (or scientist) is engaged by a member of …

    View Full Text

    Footnotes

    • Competing interests None declared.

    • Provenance and peer review Commissioned; internally peer reviewed.